Suggestions
Lou Beaulieu-Laroche
Biotech Investor | Stanford GSB MBA | MIT Neuroscience PhD
Lou Beaulieu-Laroche is a biotech analyst at Point72, currently based in the San Francisco Bay Area.1 His career journey has been marked by significant academic and professional achievements in the fields of neuroscience and biotechnology.
Academic Background
Lou completed his Ph.D. from the Massachusetts Institute of Technology (MIT) in 2021.2 During his time at MIT, he conducted groundbreaking research in neuroscience. His work culminated in a paper published in Nature, which he described as his highest scientific achievement and, interestingly, his last scientific publication.3
Career Transition
After completing his Ph.D., Lou made a transition from academia to the biotechnology industry. In June 2021, he announced that he would be joining Flagship Pioneering as a Venture Fellow.2 This move marked the beginning of his shift towards the business side of biotechnology.
Current Role
As of 2024, Lou Beaulieu-Laroche is working as a biotech analyst at Point72, a prominent asset management firm.1 This position allows him to leverage his deep scientific knowledge in the financial sector, analyzing biotechnology companies and trends.
Additional Education
In addition to his Ph.D., Lou has pursued further education to complement his transition into the business world. He attended Stanford University Graduate School of Business14, which likely provided him with the business acumen necessary for his current role in finance and biotechnology.
Research Contributions
During his academic career, Lou made significant contributions to neuroscience research. In November 2021, he was the lead author of a Nature paper that found striking differences between neurons of humans and other mammals.5 This study was conducted during his time as a graduate student at the McGovern Institute at MIT.
Lou Beaulieu-Laroche's career trajectory showcases a successful transition from academic research to the biotechnology industry and finance, combining his scientific expertise with business acumen in his current role at Point72.
